| Loss of the Spinocerebellar Ataxia type 3 disease protein ATXN3 alters transcription of multiple signal transduction pathways L Zeng, D Zhang, HS McLoughlin, AJ Zalon, L Aravind, HL Paulson PLoS One 13 (9), e0204438, 2018 | 31 | 2018 |
| Impaired oligodendrocyte maturation is an early feature in SCA3 disease pathogenesis KH Schuster, AJ Zalon, H Zhang, DM DiFranco, NR Stec, Z Haque, ... Journal of Neuroscience 42 (8), 1604-1617, 2022 | 23 | 2022 |
| Antisense Oligonucleotide Therapy Targeted Against ATXN3 Improves Potassium Channel–Mediated Purkinje Neuron Dysfunction in Spinocerebellar Ataxia Type 3 DD Bushart, AJ Zalon, H Zhang, LM Morrison, Y Guan, HL Paulson, ... The Cerebellum 20, 41-53, 2021 | 20 | 2021 |
| Antisense Oligonucleotide Silencing Reverses Abnormal Neurochemistry in Spinocerebellar Ataxia 3 Mice HS McLoughlin, K Gundry, O Rainwater, KH Schuster, IG Wellik, AJ Zalon, ... Annals of Neurology 94 (4), 658-671, 2023 | 9 | 2023 |
| ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice KH Schuster, AJ Zalon, DM DiFranco, AF Putka, NR Stec, SI Jarrah, ... Molecular Therapy 32 (5), 1359-1372, 2024 | 4 | 2024 |
